""Remdesivir, known also by its brand name "Veklury," is normally used for adults and children over 12 requiring hospitalization for covid-19, and is normally given in a vein by intravenous (IV) infusion one time each day for up to 10 days."
I am of the opinion that the FDA required IPIX to conduct the trial at less than the dosage we requested, but now I find out that we were only giving out the lower range of the DOSINGS that Rem.... is given -- so where in reality is the apples to apples comparison of IPIX to Rems....? "
For the benefit of the person making the comment and noting that the article quoted said "for up to 10 days": Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 Conclusions: In patients with severe Covid-19 not requiring mechanical ventilation, our trial did not show a significant difference between a 5-day course and a 10-day course of remdesivir. With no placebo control, however, the magnitude of benefit cannot be determined. https://pubmed.ncbi.nlm.nih.gov/32459919/
What the commenter described as "the lower range of the DOSINGS that Rem.... is given", which is actually the duration of dosings and not the amount, seems to be the Standard of Care duration. If not, I believe it would have been improper to use it as the SOC in the B-CV trial.
Again, my post is directed to someone who commented on your link and not to you. Obviously (you posted the link without comment).
Reading the article you posted recently (link attached below)I came across the below paragraph:
"Remdesivir, known also by its brand name "Veklury," is normally used for adults and children over 12 requiring hospitalization for covid-19, and is normally given in a vein by intravenous (IV) infusion one time each day for up to 10 days."
I am of the belief that the FDA limited the dosage far below what IPIX requested for the trial, the patients were mostly very severe with next to no moderate patients, and now we find out that the dosing days for the trial was limited to 3 days for 25% of patients and 5 days for the remaining patients. All in all, both the dosage and dosings were quite limited due to normal dosing for Rems.... so Brilacidin not performing to the level we expected was a given before the trial even began.
Kind of like going hunting with blanks and being disappointed when none of your shots on target were able to bring down your target.
This is why I feel the CU data is the actual part of the testing that will be able to show somewhat what Brilacidin can really do against Covid.
News 
Market Data 
Discover 
